LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

Search

Abbott Laboratories

Open

SectorGezondheidszorg

112.58 0.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

111.49

Max

113.72

Belangrijke statistieken

By Trading Economics

Inkomsten

-135M

1.6B

Verkoop

90M

11B

K/W

Sectorgemiddelde

29.778

121.746

EPS

1.5

Dividendrendement

2.17

Winstmarge

14.46

Werknemers

115,000

EBITDA

-491M

2.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+24.93% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.17%

2.26%

Volgende Winsten

15 apr 2026

Volgende dividenddatum

13 feb 2026

Volgende Ex Dividend datum

14 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-19B

193B

Vorige openingsprijs

112.36

Vorige sluitingsprijs

112.58

Nieuwssentiment

By Acuity

33%

67%

79 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Abbott Laboratories Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 jan 2026, 18:36 UTC

Winsten
Belangrijke Marktbewegers

Abbott Laboratories Raised Prices, Prompting Sales Slump -- Update

22 jan 2026, 13:23 UTC

Winsten
Belangrijke Marktbewegers

Abbott Laboratories 4Q Sales Grow, Outlook Underwhelms

20 nov 2025, 13:14 UTC

Acquisities, Fusies, Overnames

Correction to Abbott to Acquire Exact Sciences for $21 Billion Article

20 nov 2025, 13:11 UTC

Acquisities, Fusies, Overnames

Abbott to Acquire Exact Sciences for $21 Billion -- Update

28 jan 2026, 14:48 UTC

Winsten

Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares. -- Barrons.com

23 jan 2026, 16:59 UTC

Winsten

Correction to Abbott Stock Drops Article on Jan. 22

22 jan 2026, 20:42 UTC

Winsten

Abbott Stock Is on Pace for Worst Day Since 2000. The Nutrition Business Is a Drag on Earnings. -- Barrons.com

22 jan 2026, 16:19 UTC

Winsten

Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings. -- Barrons.com

22 jan 2026, 15:22 UTC

Winsten

Abbott Stock Drops on Slumping Sales of Baby Formula and Nutrition Shakes -- WSJ

22 jan 2026, 14:41 UTC

Populaire aandelen

Stocks to Watch Thursday: Intel, P&G, GE Aerospace -- WSJ

22 jan 2026, 14:08 UTC

Marktinformatie
Winsten

Abbott Posts Disappointing 4Q -- Market Talk

22 jan 2026, 12:49 UTC

Winsten

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Device Maker. -- Barrons.com

22 jan 2026, 12:31 UTC

Winsten

Abbott Labs: Well Positioned for Accelerating Growth in 2026 >ABT

22 jan 2026, 12:30 UTC

Winsten

Abbott Labs Sees 2026 Organic Sales Growth of 6.5%-7.5% >ABT

22 jan 2026, 12:30 UTC

Winsten

Abbott Labs Sees 1Q Adj EPS $1.12-Adj EPS $1.18 >ABT

22 jan 2026, 12:30 UTC

Winsten

Abbott Labs 4Q Net $1.78B >ABT

22 jan 2026, 12:30 UTC

Winsten

Abbott Labs 4Q Sales $11.46B >ABT

22 jan 2026, 12:30 UTC

Winsten

Abbott Labs Sees FY Adj EPS $5.55-Adj EPS $5.80 >ABT

22 jan 2026, 12:30 UTC

Winsten

Abbott Labs 4Q Organic Sales Growth Up 3.0% >ABT

22 jan 2026, 12:30 UTC

Winsten

Abbott Labs 4Q Adj EPS $1.50 >ABT

22 jan 2026, 12:30 UTC

Winsten

Abbott Labs 4Q EPS $1.01 >ABT

20 nov 2025, 21:23 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 nov 2025, 16:51 UTC

Acquisities, Fusies, Overnames

Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion -- Barrons.com

20 nov 2025, 15:08 UTC

Acquisities, Fusies, Overnames

Abbott to Acquire Exact Sciences for $21 Billion -- 4th Update

20 nov 2025, 14:39 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Abbott and Exact Sciences Should Make a Good Fit -- Market Talk

20 nov 2025, 14:30 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk

20 nov 2025, 13:54 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Palo Alto Networks, Alphabet, and More -- Barrons.com

20 nov 2025, 13:51 UTC

Acquisities, Fusies, Overnames

Abbott to Acquire Exact Sciences for $21 Billion -- 3rd Update

20 nov 2025, 13:25 UTC

Acquisities, Fusies, Overnames

Abbott to Acquire Exact Sciences for $21 Billion -- 2nd Update

20 nov 2025, 13:24 UTC

Acquisities, Fusies, Overnames

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

Peer Vergelijking

Prijswijziging

Abbott Laboratories Prognose

Koersdoel

By TipRanks

24.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 138.76 USD  24.93%

Hoogste 158 USD

Laagste 122 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Abbott Laboratories - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

17

Buy

1

Hold

0

Sell

Technische score

By Trading Central

132.82 / 134.43Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

79 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat